share_log

Global Immunoglobulins Markets, 2021-2022 & 2023-2027 With Takeda Pharmaceutical Company Limited., CSL Ltd., Grifols International SA and Kedrion SpA Dominating

Global Immunoglobulins Markets, 2021-2022 & 2023-2027 With Takeda Pharmaceutical Company Limited., CSL Ltd., Grifols International SA and Kedrion SpA Dominating

2021-2022年和2023-2027年全球免疫球蛋白市場,武田藥品有限公司、CSL Ltd.、Grifols International SA和Kedrion SpA佔據主導地位
PR Newswire ·  2023/04/14 08:45

DUBLIN, April 13, 2023 /PRNewswire/ -- The "Immunoglobulins: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering.

都柏林2023年4月13日 /PRNewswire/ — “免疫球蛋白:全球市場展望” 報告已添加到 ResearchandMarkets.co 提供。

The global immunoglobulins (IG) market was estimated to be $18.5 billion in 2021. The immunoglobulins market is projected to grow at a compound annual growth rate (CAGR) of 6.2% and is expected to reach $26.3 billion by the end of 2027.

全球 免疫球蛋白IG) 市場估計是 185 億美元 在 2021 年。這個 免疫球蛋白 預計市場將以複合年增長率增長(CAGR) 爲 6.2%,預計將達到 263 億美元 到 2027 年底。

The scope of this study encompasses the current and forecast markets for normal and hyper immunoglobulins. The report segments markets based on product type and route of administration. The report surveys the competitive landscape, market dynamics and current and developing technologies. The report also analyzes the impact of COVID-19 on the market.

這項研究的範圍包括正常和高免疫球蛋白的當前和預測市場。該報告根據產品類型和給藥途徑對市場進行了細分。該報告調查了競爭格局、市場動態以及當前和正在開發的技術。該報告還分析了 COVID-19 對市場的影響。

Increasing demand for immunoglobulins in various treatments and an increase in blood donations are the key factors driving the growth of the current immunoglobulins market. However, increasing research on alternative therapies and high manufacturing and treatment costs associated with immunoglobulin products could hinder market growth. Apart from drivers and restraints, growing investments in plasma fractionation capacities and increasing research on new formulations and indications should create huge opportunities for vendors in the market.

In this report, the global immunoglobulins market has been segmented based on type, route of administration and geographical region. Based on type, the immunoglobulins market has been categorized into normal and hyperimmune globulins. Normal immunoglobulins currently dominate the market and were valued at $16.5 billion in 2021. The normal immunoglobulins market is expected to grow at a CAGR of 6.0% and reach $23.2 billion by the end of 2027.

Based on the route of administration, the immunoglobulins market has been segmented into intravenous (IV), subcutaneous (SC) and others. Among all route segments, the SC segment is expected to grow at the highest CAGR, 15.8%, during the forecast period.

The immunoglobulins market has been segmented into the following geographical regions: North America; Europe; Asia-Pacific; and Rest of the World (RoW). The North American region currently dominates the global immunoglobulins market. In 2021, this region's total revenue reached $7.8 billion, accounting for about 42% of the global market.

各種治療中對免疫球蛋白的需求增加以及獻血量的增加是推動當前免疫球蛋白市場增長的關鍵因素。但是,增加對替代療法的研究以及與免疫球蛋白產品相關的高昂製造和治療成本可能會阻礙市場增長。除了驅動因素和限制因素外,增加對血漿分餾能力的投資以及對新配方和適應症的研究越來越多,應該爲市場上的供應商創造巨大的機會。

在本報告中,根據類型、給藥途徑和地理區域對全球免疫球蛋白市場進行了細分。根據類型,免疫球蛋白市場已分爲正常球蛋白和超免疫球蛋白。正常的免疫球蛋白目前在市場上佔據主導地位,其估值爲 165 億美元 在 2021 年。正常免疫球蛋白市場預計將以6.0%的複合年增長率增長並達到 232 億美元 到 2027 年底。

根據給藥途徑,免疫球蛋白市場已分爲靜脈注射(IV)、皮下(SC)等。在所有航段中,SC路段預計將在預測期內以最高的複合年增長率增長,爲15.8%。

免疫球蛋白市場已細分爲以下地理區域: 北美; 歐洲; 亞太地區;以及世界其他地區(RoW)。北美地區目前在全球免疫球蛋白市場佔據主導地位。2021 年,該地區的總收入達到 78 億美元,約佔全球市場的42%。

Key growth factors in this region include the presence of large fractionation facilities and the increasing demand for immunoglobulins in treating various immunodeficiency disorders. The Asia-Pacific immunoglobulins market was valued at $3.6 billion in 2021.

該地區的關鍵生長因素包括大型分餾設施的存在以及治療各種免疫缺陷疾病時對免疫球蛋白的需求不斷增加。這個 亞太地區 免疫球蛋白市場的估值爲 36 億美元 在 2021 年。

The Asia-Pacific immunoglobulins market is projected to grow at a CAGR of 9.1% and reach $5.9 billion by the end of 2027. The key growth driver of this region's market is the growing domestic plasma fractionation companies in countries such as South Korea and India.

這個 亞太地區 免疫球蛋白市場預計將以9.1%的複合年增長率增長並達到 59 億美元 到 2027 年底。該地區市場的主要增長驅動力是國內血漿分餾公司在以下國家不斷壯大 大韓民國印度

Takeda Pharmaceutical Company Limited., CSL Ltd., Grifols International SA and Kedrion SpA are major players in the immunoglobulins market

武田製藥有限公司、CSL Ltd.、Grifols International SA和Kedrion SpA是免疫球蛋白市場的主要參與者

Report Includes

報告包括

  • A brief general outlook of the global market for immunoglobulins
  • Analyses of the global market trends, with historic market revenue data (sales figures) for 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Estimation of the actual market size and revenue forecast for the global immunoglobulins market in USD million terms, and corresponding market share analysis by product type, route of administration, and region
  • In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, current and future prospects in therapeutic treatments, and contributions to the overall market
  • Identification of major stakeholders and analysis of the company competitive landscape based on their recent developments, financial performance, segmental revenues, and operational integration
  • Company profiles of the market leading players
  • 全球免疫球蛋白市場的簡要總體展望
  • 分析全球市場趨勢,包括2021年的歷史市場收入數據(銷售數據)、2022年的估計值以及到2027年的複合年增長率(CAGR)預測
  • 按百萬美元估算全球免疫球蛋白市場的實際市場規模和收入預測,並按產品類型、給藥途徑和地區進行相應的市場份額分析
  • 有關影響該市場發展的主要因素(收益和行業特定挑戰)的深入信息(事實和數據),包括具體的增長趨勢、即將推出的技術、治療的當前和未來前景以及對整個市場的貢獻
  • 確定主要利益相關者,並根據其近期發展、財務業績、細分市場收入和運營整合分析公司競爭格局
  • 市場領先企業的公司概況

Key Topics Covered:

涵蓋的關鍵主題:

Chapter 1 Introduction
1.1 Market Snapshot

第 1 章簡介
1.1 市場快照

Chapter 2 Executive Summary

第 2 章執行摘要

Chapter 3 Market Overview
3.1 Immunoglobulin G (Igg)
3.2 Immunoglobulin M (Igm)
3.3 Immunoglobulin a (Iga)
3.4 Immunoglobulin E (Ige)
3.5 Immunoglobulin D (Igd)
3.6 Immunoglobulins Mechanism of Action
3.7 Clinical Use of Immunoglobulins
3.7.1 Replacement Therapy With Immunoglobulins
3.7.2 Immunoglobulin Blood Tests
3.8 Market Dynamics
3.8.1 Market Drivers
3.8.2 Market Restraints

第 3 章市場概述
3.1 免疫球蛋白 G (Igg)
3.2 免疫球蛋白 M (Igm)
3.3 免疫球蛋白 a (Iga)
3.4 免疫球蛋白 E (Ige)
3.5 免疫球蛋白 D (Igd)
3.6 免疫球蛋白的作用機制
3.7 免疫球蛋白的臨牀用途
3.7.1 免疫球蛋白替代療法
3.7.2 免疫球蛋白血液檢測
3.8 市場動態
3.8.1 市場驅動因素
3.8.2 市場限制

Chapter 4 Emerging Technologies/ Opportunities
4.1 Growing Investments in Plasma Fractionation Capacities
4.2 Increasing Research on New Formulations and Indications
4.3 Growing Opportunities in Emerging Nations
4.4 Adoption of Digital Initiatives

第 4 章新興技術/機會
4.1 對等離子體分餾能力的投資不斷增加
4.2 加強對新配方和適應症的研究
4.3 新興國家的機會越來越多
4.4 採用數字化舉措

Chapter 5 Market Breakdown by Type, Route of Administration
5.1 Immunoglobulins Market, by Type
5.1.1 Normal Immune Globulins
5.1.2 Hyperimmune Globulins
5.1.3 Market Size and Forecast
5.2 Immunoglobulins Market, by Route of Administration
5.2.1 Intravenous (Iv) Administration
5.2.2 Subcutaneous (Sc) Administration
5.2.3 Others
5.2.4 Market Size and Forecast
5.3 Normal Immunoglobulins Market, by Application
5.3.1 Primary Immune Deficiency (Pid)
5.3.2 Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)
5.3.3 Secondary Immune Deficiency (Sid)
5.3.4 Multifocal Motor Neuropathy (Mmn)
5.3.5 Other Neurological Disorders
5.3.6 Other Applications
5.3.7 Market Size and Forecast

第 5 章按類型、管理途徑劃分的市場細分
5.1 按類型劃分的免疫球蛋白市場
5.1.1 正常免疫球蛋白
5.1.2 超免疫球蛋白
5.1.3 市場規模和預測
5.2 按給藥途徑劃分的免疫球蛋白市場
5.2.1 靜脈注射 (Iv) 給藥
5.2.2 皮下 (Sc) 給藥
5.2.3 其他
5.2.4 市場規模和預測
5.3 按應用劃分的正常免疫球蛋白市場
5.3.1 原發性免疫缺陷 (Pid)
5.3.2 慢性炎症性脫髓鞘性多發性神經病 (Cidp)
5.3.3 繼發性免疫缺陷 (Sid)
5.3.4 多竈性運動神經病 (Mmn)
5.3.5 其他神經系統疾病
5.3.6 其他應用程序
5.3.7 市場規模和預測

Chapter 6 Market Breakdown by Region
6.1 Global Immunoglobulins Market Size, by Region
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Rest of the World

第 6 章按地區劃分的市場細分
6.1 按地區劃分的全球免疫球蛋白市場規模
6.2 北美
6.3 歐洲
6.4 亞太地區
6.5 世界其他地區

Chapter 7 Competitive Landscape
7.1 Recent Key Developments
7.2 Product Launches
7.3 Mergers and Acquisitions
7.4 Business Expansions
7.5 Agreements and Collaborations
7.6 Clinical Trials Landscape

第 7 章競爭格局
7.1 最近的主要進展
7.2 產品發佈
7.3 合併和收購
7.4 業務擴展
7.5 協議和合作
7.6 臨牀試驗概況

Chapter 8 Covid-19 Impact: Immunoglobulins Market
8.1 Covid-19 Impact on the Immunoglobulins Market
8.1.1 Convalescent Plasma (Cp) Therapy and Hyperimmune Globulins for Covid-19 Treatment

第 8 章 Covid-19 的影響:免疫球蛋白市場
8.1 Covid-19對免疫球蛋白市場的影響
8.1.1 用於治療Covid-19的恢復期血漿(Cp)療法和超免疫球蛋白

Chapter 9 Company Profiles

第 9 章公司簡介

  • Adma Biologics Inc.
  • Baxter International
  • Bio Products Laboratory Ltd.
  • China Biologic Products Inc.
  • Csl Ltd.
  • Grifols International S.A.
  • Innovative Research
  • Intas Pharmaceuticals Ltd.
  • Kedrion Spa
  • Lfb S.A.
  • Octapharma AG
  • Sanquin
  • Takeda Pharmaceutical Company Limited.
  • Adma Biologics Inc.
  • 巴克斯特國際
  • 生物產品實驗室有限公司
  • 中國生物製品有限公司
  • Csl Ltd.
  • 格里福爾斯國際有限公司
  • 創新研究
  • 英塔斯製藥有限公司
  • Kedrion 水療中心
  • Lfb S.A.
  • Octapharma AG
  • 桑昆
  • 武田製藥株式會社

For more information about this report visit

有關此報告的更多信息,請訪問

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

關於 ResearchandMarkets
ResearchandMarkets.com是全球領先的國際市場研究報告和市場數據來源。我們爲您提供有關國際和地區市場、關鍵行業、頂級公司、新產品和最新趨勢的最新數據。

Media Contact:

媒體聯繫人:

Research and Markets
Laura Wood, Senior Manager
[email protected]

研究與市場
勞拉·伍德,高級經理
[電子郵件保護]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

如需瞭解歐洲安全局的辦公時間,請致電 +1-917-300-0470
如需美國/加拿大免費電話,請致電 +1-800-526-8630
如需瞭解格林尼治標準時間辦公時間,請致電 +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

美國傳真:646-607-1904
傳真(美國境外):+353-1-481-1716

Logo:

徽標:

SOURCE Research and Markets

來源:研究與市場

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論